Macquarie Group Ltd. raised its stake in shares of Alkermes PLC (NASDAQ:ALKS) by 175.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 169,940 shares of the company’s stock after acquiring an additional 108,229 shares during the period. Macquarie Group Ltd. owned approximately 0.11% of Alkermes PLC worth $9,851,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Daiwa SB Investments Ltd. acquired a new position in shares of Alkermes PLC in the second quarter valued at approximately $166,000. Greenwood Capital Associates LLC grew its holdings in Alkermes PLC by 1.1% during the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after acquiring an additional 41 shares in the last quarter. US Bancorp DE grew its holdings in Alkermes PLC by 366.4% during the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after acquiring an additional 3,122 shares in the last quarter. Insight Capital Research & Management Inc. acquired a new position in Alkermes PLC during the 2nd quarter worth approximately $232,000. Finally, Aviance Capital Partners LLC acquired a new position in Alkermes PLC during the 2nd quarter worth approximately $232,000. Institutional investors and hedge funds own 98.51% of the company’s stock.

In related news, Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total value of $82,365.00. Following the transaction, the director now owns 9,500 shares of the company’s stock, valued at approximately $521,645. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of Alkermes PLC stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $51.29, for a total value of $695,800.14. Following the completion of the transaction, the chief accounting officer now directly owns 70,455 shares in the company, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,066 shares of company stock worth $930,280. 5.34% of the stock is owned by corporate insiders.

Several research analysts have commented on the stock. Barclays PLC cut shares of Alkermes PLC from an “overweight” rating to a “hold” rating in a report on Monday. J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Saturday, July 1st. BidaskClub cut shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. ValuEngine cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Jefferies Group LLC set a $69.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Friday, August 25th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $64.13.

Alkermes PLC (NASDAQ ALKS) opened at 50.29 on Monday. The firm has a 50-day moving average of $51.08 and a 200 day moving average of $55.51. Alkermes PLC has a 52 week low of $41.93 and a 52 week high of $63.40. The firm’s market capitalization is $7.73 billion.

Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $216.54 million. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The company’s revenue was up 12.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.01) earnings per share. Analysts predict that Alkermes PLC will post ($0.04) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/alkermes-plc-alks-holdings-raised-by-macquarie-group-ltd/1634494.html.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.